Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Coldstream Capital Management Inc.

Coldstream Capital Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 48.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,602 shares of the biopharmaceutical company’s stock after buying an additional 523 shares during the period. Coldstream Capital Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $522,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 1.8% during the second quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock valued at $4,336,064,000 after purchasing an additional 240,534 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Alnylam Pharmaceuticals by 0.8% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock worth $1,192,988,000 after buying an additional 33,696 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Alnylam Pharmaceuticals by 5.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock worth $946,466,000 after buying an additional 185,783 shares during the period. Geode Capital Management LLC increased its position in Alnylam Pharmaceuticals by 3.3% in the second quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after buying an additional 75,936 shares during the period. Finally, American Century Companies Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 1.9% during the second quarter. American Century Companies Inc. now owns 1,793,846 shares of the biopharmaceutical company’s stock valued at $584,957,000 after acquiring an additional 33,411 shares during the period. Institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling

In other news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the completion of the transaction, the executive vice president owned 21,264 shares in the company, valued at approximately $9,615,155.52. This trade represents a 36.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 10,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $451.27, for a total transaction of $4,512,700.00. Following the completion of the transaction, the chief executive officer directly owned 65,409 shares in the company, valued at $29,517,119.43. This represents a 13.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 78,328 shares of company stock worth $35,705,793 in the last ninety days. Insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Evercore ISI lifted their price objective on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the company an “outperform” rating in a research report on Thursday, September 11th. Wolfe Research raised Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a report on Monday, August 4th. JPMorgan Chase & Co. reduced their price objective on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research report on Monday, October 13th. Morgan Stanley raised their target price on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an “equal weight” rating in a research report on Monday, October 6th. Finally, Citigroup boosted their price target on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Twenty-three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $482.17.

Alnylam Pharmaceuticals Trading Up 3.6%

Shares of Alnylam Pharmaceuticals stock opened at $445.12 on Friday. The business has a fifty day simple moving average of $455.86 and a 200-day simple moving average of $394.58. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The firm has a market cap of $58.81 billion, a price-to-earnings ratio of -180.21 and a beta of 0.30. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.